AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00827294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
Study NCT01840098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control/carbohydrate
Study NCT01840098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 36 hour fasting
Study NCT04041245 — intervention group
Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian.
Study NCT00638976 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: eptifibatide
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
Study NCT00638976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
Study NCT00483002 — intervention group
Intervention type: DRUG
Intervention: varenicline
Description: As prescribed by physician in usual clinical practice.
Study NCT02556268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRIPLA
Description: 600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
Study NCT02556268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMPLERA
Description: 200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
Study NCT02556268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRIBILD
Description: 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
Study NCT02556268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIUMEQ
Description: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
Study NCT02556268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral protease inhibitor
Description: Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
Study NCT01135758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
Study NCT01829555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
Study NCT05328128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toilet training
Description: As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
Study NCT03147586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bio-tech and omega-3 plus
Description: immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
Study NCT03147586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03799809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrabronchial Voriconazole instillation
Description: Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
Study NCT01282645 — intervention group
Intervention type: DEVICE
Intervention: PSI in PEEK
Description: A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
Study NCT05301296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination of the breast for early detection of Cancer
Description: Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
Study NCT02256761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX - multiple escalating dose
Study NCT02256761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02256761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX - single dose
Study NCT02256761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high caloric meal
Description: 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
Study NCT04327232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Mineralocorticoid Receptor Antagonists
Study NCT04327232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT02002923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
Study NCT02002923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
Study NCT02092662 — intervention group
Intervention type: OTHER
Intervention: stroke
Description: task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
Study NCT02092662 — intervention group
Intervention type: OTHER
Intervention: Healthy controls
Description: no treatment
Study NCT00530933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous posterior tibial nerve stimulation
Description: Once weekly for 30 minutes
Study NCT00530933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: 30 minutes once weekly
Study NCT00530933 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous tibial nerve stimulation
Description: Once weekly for 30 minutes
Study NCT03573947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg intravenously every 3 weeks
Study NCT03573947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg intravenously over 30 minutes
Study NCT03573947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
Study NCT03777007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPARTA force plate
Description: The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
Study NCT00885755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard taxane therapy
Description: As prescribed
Study NCT00885755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
Study NCT00885755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
Study NCT02193373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Medicine
Description: Osteopathic Manual Medicine
Study NCT02193373 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Osteopathic Manual Medicine
Study NCT01266460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
Description: Given IV
Study NCT01266460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05600439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareME
Description: CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision.
Study NCT03566121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic ultrasound / Urodynamic ultrasound
Description: Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
Study NCT03566121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic ultrasound / Urodynamic ultrasound
Description: Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
Study NCT03839758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSA standard
Description: Glenoid preparation will be done with 2D CT-Scan
Study NCT03839758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RTSA standard
Description: Glenoid preparation will be done with 2D CT-Scan
Study NCT03839758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSA Blueprint
Description: Glenoid preparation will be done with Blueprint software
Study NCT03839758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RTSA Blueprint
Description: Glenoid preparation will be done with 2D CT-Scan
Study NCT02797158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI procedure
Description: Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
Study NCT01704456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
Study NCT01704456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
Study NCT01286571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: one oral single dose per subject
Study NCT03914677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine Oral Tablet
Description: nicotinic antagonist (ganglionic blocker)
Study NCT04566146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: scapular muscle training, serratus anterior strength, scapular stabilization exercises
Description: patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
Study NCT02383771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: (Ticagrelor 90mg Bid) x 7days
Study NCT02383771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Description: (Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
Study NCT02383771 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No Anti-platelet Therapy
Study NCT02383771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin + Ticagrelor
Description: Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
Study NCT01873248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
Study NCT02779621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-collecting a vaginal sample with a swab for HPV testing
Description: The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
Study NCT02779621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of cervical sample for routine cervical screening
Description: This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
Study NCT02779621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of cervical sample for routine cervical screening
Description: This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
Study NCT00877929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80
Description: Telmisartan 80 mg
Study NCT00877929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10
Description: Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Study NCT00877929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10
Description: Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Study NCT01486979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, 10 mcg
Description: One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
Study NCT01486979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol, 25 mcg
Description: One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
Study NCT01822912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Disease Management Program
Description: Subjects will be assessed 3 times a week while in SNF.
Study NCT01822912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heart Failure Usual Care
Description: Subjects will receive standard of care.
Study NCT04678557 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-01 Combination Product
Description: PEC-01 cells loaded into an Encaptra Drug Delivery System
Study NCT01759095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic multidrug blister pack
Description: At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
Study NCT02934464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Study NCT01493921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 gel
Description: Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Study NCT03447912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
Study NCT03015688 — intervention group
Intervention type: RADIATION
Intervention: x-ray images
Study NCT01049698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: 3 d/wk resistance training
Study NCT01049698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training + Diet
Description: 3 d/w resistance training plus 600 kcal/d deficit
Study NCT02165202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine
Description: Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
Study NCT02165202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.